史赛克公司(SYK.US)2025年第三季度业绩电话会
文章语言：
简
繁
EN
分享
纪要
原文
会议摘要
Stryker achieved 9.5% organic sales growth in Q3 2025, driven by Orthopedics, Med-Surg, and Neurotechnology, with notable double-digit growth in Orthopedics and 6.3% international sales growth. The company overcame tariff challenges to report 11.1% adjusted EPS growth, completed acquisitions of Guard Medical and Advanced Medical Balloons, and raised full-year guidance to 9.8%-10.2% organic sales growth. Stryker is planning for continued margin expansion, active M&A, and hosting an Investor Day on November 13 to discuss long-term strategies and innovations.
会议速览
Stryker's Q3 2025 Earnings Call: CEO Addresses Forward-Looking Statements and Non-GAAP MeasuresThe call outlines Stryker's third quarter 2025 earnings, with a focus on forward-looking statements, potential differences from actual results, and the inclusion of non-GAAP financial measures, while emphasizing the availability of reconciliations in SEC filings.
Strong Q3 Earnings, Organic Growth, and Strategic Acquisitions Highlight Striker's Financial Health and Future ProspectsStriker reports robust third-quarter earnings with 9.5% organic sales growth and 11.1% adjusted EPS growth. Highlights include strong procedural volumes, successful M&A activities, and ongoing integration of Anari, with plans to maintain momentum and raise full-year 2025 outlook.
Stryker's Q3 Financial Update: Sales Growth, Strategic Outlook, and Upcoming Investor DayDiscussed third quarter financial achievements, including 9.5% organic sales growth and 11.1% increase in adjusted earnings per share. Highlighted positive pricing trends and foreign currency benefits. Anticipated Stryker's Investor Day on November 13, featuring insights on long-term strategy and product innovations.
Strong Q3 Sales Growth Driven by Orthopedics and Vascular SegmentsQuarterly segment performance highlights include robust organic sales growth across med-surg tech, instruments, endoscopy, medical, vascular, and neuro cranial segments. Notable achievements are in orthopedics, with strong US knee, hip, trauma, and extremities business growth. Adjusted gross margin and operating margin improved, despite tariff penalties. Full year 2025 guidance for organic net sales growth is raised to 9.8% to 10.2%, with adjusted earnings per share expected between $13.50 and $13.60.
Analysis of Global Procedure Volumes and Equipment Market Health in Q2Discussion highlights robust procedure volumes impacting implants and capital markets, noting strong installations and cash purchases. Despite slight medical market variability and supply chain disruptions, the sector anticipates double-digit growth, underscoring overall market health and positive outlook for the fourth quarter.
Analyzing Q4 Margin Growth Amid Tariff ChallengesDiscusses factors contributing to fourth quarter sales and margin growth, highlighting operational margin improvements and the offsetting effect of tariffs.
Sustained Growth, M&A Strategy, and Tariff Impact on Future FinancialsThe dialogue focuses on maintaining a 10% organic growth rate, discussing sustainable high growth, M&A strategies including potential large deals, and the impact of increasing tariffs on margins. The speaker emphasizes the company's strong balance sheet, priority on value-creating acquisitions, and plans for investor transparency.
Orthopedics Market Health & Pricing StrategyDiscusses the robust growth in the orthopedics market, driven by Mako's adoption and new innovations, while addressing slight price pressures and strategies for maintaining positive pricing trends.
Expanding International Presence and Recovery of US Business Post-ChallengesThe focus has been on US business recovery, overcoming sales force challenges, and launching a successful arterial product. International expansion is anticipated to significantly impact in the second half of next year, leveraging existing infrastructure.
Q&A on Sales Growth, Stocking Impact, and Siemens Partnership in Neurovascular RoboticsThe dialogue discusses expectations for sustained double-digit sales growth post-quarter, the completion of inventory stocking by Q1, and plans for a partnership with Siemens in neurovascular robotics, with further details to be disclosed at a later time.
Analysis of Ortho Category Growth and SustainabilityDiscussion on the robust performance of the ortho category, driven by record Mako installations and business mix, with insights into the sustainability of this growth.
Medical Business Growth Despite Supply Chain DisruptionsDespite lingering supply chain issues, the medical business is expected to perform strongly, with an acceleration in Q4 leading to a 10% annual growth. Key drivers include product launches like LP 35 in Europe and consistent double-digit growth across diverse business lines, supported by a strong order book.
Leveraging Orthopedic Portfolio Growth in ASCsA discussion on the advantages of procedure shifts to Ambulatory Surgery Centers (ASCs), highlighting the company's leadership in total shoulder and potential total ankle procedures, enhancing portfolio leverage across capital, disposables, and inputs.
Small Product Acquisitions Expand Market ReachTwo small acquisitions introduced products in wound care and fecal incontinence, enhancing sales rep offerings and expanding into new patient care areas. Expect continued strategic tuck-in acquisitions.
Analysis of Healthcare Demand, CapEx Trends, and Future Margin Expansion StrategiesDiscussed factors influencing healthcare demand, capital expenditure trends amidst policy uncertainties, and future strategies for margin expansion, emphasizing robust growth and strong market position.
Strong Growth in Trauma Business with Product Innovations and LeadershipThe trauma attorney business is thriving, driven by a robust portfolio, strong leadership, and product innovations like Bolar plates. Despite limited Mako shoulder impact, the core trauma segment, including Pangea and Blueprint software, is growing at robust rates, with full Mako shoulder launch anticipated in the first half of next year.
Performance Review and Future Outlook in Foot and Ankle SurgeryA discussion on the current performance of foot and ankle surgical products, highlighting strong results in total ankle and augment, while noting room for improvement in core plates and nails, with optimism for future advancements.
Updates on Peer-to-Trial Progress, Rcx Product Launch, and Guard Medical AcquisitionThe dialogue provides updates on the status of a peer-to-trial, revealing that results are expected sometime next year. It also discusses the successful launch of the Rcx product, which is performing well in the market. Lastly, the acquisition of Guard Medical is clarified as a strategic move to enhance sales calls by integrating products into existing sales reps' portfolios, without signaling an immediate expansion into broader wound care markets.
Pricing Power Across Businesses Discussed Amid Positive Product CycleA discussion on maintaining pricing power across various business lines, despite anniversarizing price increases, highlights confidence in future pricing opportunities driven by new products and innovation.
Investor Day Updates, Tariff Impact, and Financial GoalsThe call discussed upcoming Investor Day where long-term financial goals, including organic growth, operating margins, EPS growth, and free cash flow conversion, will be updated. Current tariff environment was addressed, forecasting a $200 million impact for the year. Closing remarks emphasized future business updates at Investor Day and upcoming quarterly results.
要点回答
Q：What were the highlights in terms of organic sales growth across different business segments for the third quarter?
A：The highlights for the third quarter included widespread demand across businesses with high single digit growth from med-surg neurotechnology and double digit growth from orthopedics. Geographically, the U.S. had 10.6% organic sales growth with double digit growth in vascular, trauma and extremities, neuro, cranial and instruments businesses, while international sales grew by 6.3% organically with notable contributions from South Korea, Japan, and emerging markets.
Q：What acquisitions did Stryker complete during the third quarter and what do they add to the company's portfolio?
A：Stryker completed two small acquisitions during the third quarter: Guard Medicals' negative pressure wound treatment products, which strengthen its orthopedic instruments offerings, and Advanced Medical Balloons, which brings novel patient care products to its sage business. These acquisitions demonstrate Stryker's commitment to deals that deepen its portfolio and enhance growth.
Q：How is Stryker's outlook for the remainder of the year and what is the reason for raising its full year outlook?
A：Stryker is experiencing good momentum exiting the third quarter and expects a strong finish to the year, leading to the raising of its full year 2025 outlook. The company is now on track to deliver a second consecutive year of 100 basis points of adjusted operating margin extension due to strong execution and the sustained growth and earnings power of its businesses.
Q：What significant developments are taking place in the integration of Anari and what recent product innovations have been made by Stryker?
A：The integration of Anari is progressing well, with the business being successfully converted to Stryker's systems, including the onboarding of sales professionals. Anari delivered double-digit pro forma organic sales growth with robust procedural growth in the teens, partially offset by destocking which is being worked through. Notable recent product innovations by Stryker include Lipak 35 in Europe at the end of the quarter.
Q：What is the projected performance of Stryker's areas of business for the remainder of the year and what upcoming event is scheduled for November 13?
A：Stryker expects its areas of business to deliver double-digit pro forma sales growth for the remainder of the year, with the anari area of business contributing approximately $590 million in sales for the ten months it was part of Stryker. An upcoming event scheduled for November 13 is the Investor Day, which will include a webcast discussion of the company's long-term strategy and a product fair showcasing exciting products.
Q：What were the detailed financial results for the third quarter, including organic sales growth and adjusted earnings per share?
A：Detailed financial results for the third quarter include an organic sales growth of 9.5%, with a pricing impact of 0.4% and a currency impact of 0.7%. Adjusted earnings per share of $3.19 were up 11.1% from the same quarter last year, driven by strong sales growth and margin expansion, partially offset by higher interest expense. Foreign currency translation had a favorable impact of 3 cents on adjusted earnings per share.
Q：What were the growth rates and market performances in the orthopedics business for the recent quarter?
A：The organic sales growth in the orthopedics business for the recent quarter was 11.4%, with 12.9% in the U.S. and 7.8% internationally. The U.S. knee business grew 8.4% organically, the U.S. hip business 8.7% organically, and the U.S. trauma and extremities business grew 13.2% organically. Additionally, the international orthopedics organic growth was 7.8% with a strong performance from emerging markets.
Q：How is the company performing in cash flow and earnings guidance for the full year?
A：The company's year-to-date cash from operations was $2.9 billion, driven by year-over-year working capital improvements. The full-year 2025 guidance has been raised and now expects organic net sales growth of 9.8% to 10.2% and adjusted earnings per share in the range of $13.50 to $13.60. The updated sales guidance includes a modestly favorable pricing impact and a slightly positive impact from foreign exchange.
Q：What are the global trends in procedure volumes, equipment markets, and capital equipment?
A：Global procedure volumes are very healthy, positively affecting implants and small capital equipment. The capital equipment market is strong with healthy balance sheets. Procedure growth is strong, and the order book for medical, as described, is robust with timing delays in installations but very strong growth expected in the fourth quarter.
Q：What factors should be considered for achieving a step-up in sales and margins from the third to the fourth quarter?
A：To achieve a step-up in sales and margins from the third to the fourth quarter, focus on continued margin improvement by driving upside on gross margins and managing sales growth. Tariffs will be a significant offset to otherwise larger margin expansion in the fourth quarter, but operationally, better margins are expected.
Q：How has the supply chain disruptions impacted the company's performance and what is the expected growth despite these challenges?
A：The company has faced supply chain disruptions in emergency care throughout the year, resulting in challenges that would have been overcome for a significantly higher year-over-year growth if not for these disruptions. However, the markets the company plans are very healthy despite these challenges.
Q：Does the company plan to maintain the current growth momentum into the following year and how will tariffs impact expansion?
A：The guidance suggests maintaining the current momentum into the following year, with a focus on driving better margins despite the challenging impact of tariffs. However, the exact puts and takes for next year's performance, including margin expansion, will be influenced by the increasing year-over-year impact of tariffs.
Q：What is the company's organic growth rate and how does it view the sustainability of this growth?
A：The company has grown organically by approximately 10% for four consecutive years, with a high single-digit growth in the last year. The business is described as sustainable and durable, with plans for continued high growth in the future.
Q：What does the company plan to do with its balance sheet and acquisition strategy?
A：The company has a strong balance sheet and is prepared to undertake larger deals if they are deemed value-creating for the company. The number one use of capital is prioritized as acquisitions, and the company remains actively seeking opportunities.
Q：How does the company perceive the health of the orthopedics market and its preparations for potential disruption?
A：The company views the orthopedics market as healthy and is positioned to capitalize on any potential disruption, such as the announced spin-out of a competitor's orthopedic business. The knee business is performing extremely well, bolstered by the adoption of Mako for knees and other new products. The company is excited about upcoming changes that will further improve the Mako system and introduce new surgical innovations.
Q：What factors have contributed to the company's pricing power?
A：The company has been able to drive positive prices for the organization over the last several quarters, a result of work done a few years ago. This pricing power is attributed to continued positive pricing across multiple business segments, despite recent price pressures in the orthopedics market that haven't been seen before. The company aims to maintain and build on its pricing strategies moving forward.
Q：How is the company's international expansion strategy for Nari planned and what is the expected timeline?
A：The company's focus has been primarily on the U.S., but it has started to expand internationally with Nari, although this area has not taken off yet. The company plans for international expansion for Nari to really start impacting results in the second half of the following year, leveraging the infrastructure that was part of the reason for acquiring Nari in the first place.
Q：What is the company's view on growth in Q4 and future prospects?
A：The company expects double-digit growth in Q4 and into Q1, with the drag from previous stockbuilding being fully addressed by the end of Q1. Q4 will also see the debut of new arterial products with positive feedback. Growth is anticipated to accelerate in Q2 without the previous stockbuilding impact. The company remains excited about the potential for double-digit growth in the future.
Q：Can the company disclose any updates on the partnership with Siemens regarding neurovascular robotics?
A：The company disclosed that they would provide updates when appropriate, but at the time of the conversation, no further details were offered regarding the partnership with Siemens on neurovascular robotics.
Q：What is driving the performance in the orthopedic other category and how durable is this growth?
A：The performance in the orthopedic other category is being driven by recent product offerings and the momentum from these new offerings. The company is confident about the durability of this growth, as these new products have been well received in the market.
Q：What factors contributed to the revenue growth in the medical category?
A：The revenue growth in the medical category was attributed to the record installation of Mako, and a strong business mix with outright purchases driving revenue.
Q：What is the expected performance in the fourth quarter for the medical business?
A：The medical business is expected to show positive performance throughout the fourth quarter with an acceleration in October. This is due to the anticipated rebound in the fourth quarter to achieve 10% year-over-year growth, driven by an increase in procedures such as total shoulders and potentially total ankles moving into the ambulatory surgical center (ASC) environment.
Q：What are the drivers behind the 10% sales growth for the medical segment in the year?
A：The drivers behind the 10% sales growth for the medical segment include the anticipated acceleration of performance across all lines of business in medical, with specific mention of products like LP35 showing strong performance in the third quarter and expected to continue in the fourth. The business is known for its consistent double-digit growth year after year, supported by a strong order book and despite supply chain challenges.
Q：How are the competitive dynamics in the ASCs impacting Striker's position?
A：The competitive dynamics in the ASCs are positive for Striker as the procedures are moving to the ASC, which allows Striker to leverage its full portfolio, including capital, disposables, and implants. With the market leader position in total shoulders and potential movement of higher acuity cases to the ASC, Striker benefits from a broader portfolio and the growth continues to be very high in the ASC.
Q：What are the characteristics of the two smaller product acquisitions mentioned and their potential impact?
A：The two smaller product acquisitions include a negative pressure wound treatment device (NPC) that is used in orthopedic procedures and a balloon product for fecal incontinence, used in intensive care units. The NPC is a lower-cost solution that fits easily into the sales process of orthopedic instruments. The balloon product addresses a troubling condition for patients and provides dignity and care. These products are seen as elegant solutions that fit well into the company's sales strategy.
Q：Are there concerns about the pull-forward of demand due to uncertainties around healthcare exchanges?
A：There is no view that the third quarter's growth is due to the pull-forward of demand resulting from uncertainties around healthcare exchanges. Instead, the continued strong demand and robust growth rate suggest that the procedures are necessary due to pain management needs and there is no anxiety from surgeons about a falloff in procedures. The focus is on the robust market growth and the belief that the majority of the company's capital equipment is tied to procedures that hospitals need for their operations.
Q：What are the sentiments regarding capital equipment purchases in the current quarter and the future?
A：There is a strong sentiment regarding capital equipment purchases in the current quarter, with large capital equipment showing very strong performance and minimal cancellations of orders. Hospitals have budgets and plans to proceed with purchasing despite external challenges.
Q：What performance metrics are provided for the third quarter of 2020 to 2021?
A：The performance metric provided for the third quarter of 2020 to 2021 is a 25.6% expansion, indicating an increase from the previous year.
Q：What is the status of the Mako shoulder launch?
A：The Mako shoulder is in a limited launch phase and has been very well received, with plans for a full launch expected in the first half of the next year.
Q：What is the current status of the trauma business and its product innovations?
A：The trauma business is described as 'on fire' with strong performance, particularly from the shoulder business and new product innovations such as Bolar plates for distal radius. Core trauma is experiencing robust growth with Pangea, and while foot and ankle is currently soft, the company sees upside potential for this segment going into the next year.
Q：When might results from the peer-to-peer trial be available?
A：Results from the peer-to-peer trial are expected to start showing sometime next year, with the company anticipating discussions about this in the following year.
Q：What is the significance of the Guard medical acquisition and its impact on the advanced wound care market?
A：The Guard medical acquisition is seen as a move that optimizes sales calls rather than creating a new business line. It is described as a product that drops into the existing sales rep bag rather than representing the creation of a new, broader strategy in the advanced wound care market.
Q：What is the company's view on future pricing and product cycle in orthopedics?
A：The company believes that due to overall business execution, new product innovations, and pricing power, it will have opportunities for pricing across all businesses, with specific actions varying by business line. However, they expect to maintain pricing power going forward.
Q：Will the company outline long-term financial goals and how will the current tariff environment affect 2026?
A：The company plans to update long-term financial goals, including current views on margins, during the upcoming Investor Day. They expect to see the impact of the current tariff environment on operations, with a forecasted $200 million impact for the year, although this is subject to change given the fluidity of the situation.
